Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHA:600572)
China · Delayed Price · Currency is CNY 4.130
-0.040 (-0.96%)
Oct 28, 2026, 11:29 AM CST
SHA:600572 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 6,736 | 6,382 | 6,426 | 6,652 | 5,945 | 6,531 |
Other Revenue | 91.43 | 91.43 | 89.02 | 80.59 | 54.95 | 37.67 |
| 6,828 | 6,473 | 6,515 | 6,733 | 6,000 | 6,568 | |
Revenue Growth | 3.80% | -0.64% | -3.23% | 12.21% | -8.64% | 11.15% |
Cost of Revenue | 3,088 | 3,051 | 3,101 | 2,835 | 2,470 | 2,626 |
Gross Profit | 3,740 | 3,422 | 3,414 | 3,897 | 3,531 | 3,942 |
Selling, General & Admin | 2,683 | 2,564 | 2,480 | 2,832 | 2,581 | 2,964 |
Research & Development | 240.62 | 262.22 | 300.02 | 298.09 | 195.72 | 202.49 |
Other Operating Expenses | 64.38 | 65.43 | 52.8 | -38.49 | 62.99 | 64.65 |
Operating Expenses | 2,985 | 2,893 | 2,834 | 3,093 | 2,840 | 3,268 |
Operating Income | 754.62 | 529.22 | 580.51 | 804.32 | 690.41 | 674.18 |
Interest Expense | -1.77 | -7.79 | -20.79 | -36.4 | -49.47 | -73.22 |
Interest & Investment Income | 82.93 | 95.48 | 101.92 | 135.27 | 89.35 | 2,611 |
Currency Exchange Gain (Loss) | -1.75 | -1.75 | 5.22 | 3.09 | -1.11 | 0.06 |
Other Non Operating Income (Expenses) | -13.23 | -11.16 | -1.65 | -21.98 | -3.76 | -9.31 |
EBT Excluding Unusual Items | 820.8 | 604 | 665.22 | 884.3 | 725.42 | 3,203 |
Gain (Loss) on Sale of Investments | -156.54 | 25.64 | 30.27 | -146.04 | -238.23 | -714.69 |
Gain (Loss) on Sale of Assets | -0.12 | 4.89 | 16.91 | 35.68 | 36.02 | 42.22 |
Asset Writedown | -23.69 | -26.81 | -1.82 | -7.18 | -1.84 | -95.71 |
Other Unusual Items | 8.15 | 37.45 | 69.36 | 0.93 | 68.64 | 92.55 |
Pretax Income | 648.6 | 645.17 | 779.94 | 767.69 | 590.01 | 2,527 |
Income Tax Expense | 170.45 | 153.62 | 121.59 | 92.97 | 129.89 | 391.13 |
Earnings From Continuing Operations | 478.16 | 491.55 | 658.35 | 674.72 | 460.12 | 2,136 |
Minority Interest in Earnings | -21.42 | -17.19 | -35.94 | -83.15 | -102 | -118.31 |
Net Income | 456.74 | 474.36 | 622.42 | 591.57 | 358.12 | 2,017 |
Net Income to Common | 456.74 | 474.36 | 622.42 | 591.57 | 358.12 | 2,017 |
Net Income Growth | -33.61% | -23.79% | 5.21% | 65.19% | -82.25% | 345.06% |
Shares Outstanding (Basic) | 2,514 | 2,497 | 2,490 | 2,572 | 2,558 | 2,586 |
Shares Outstanding (Diluted) | 2,514 | 2,497 | 2,490 | 2,572 | 2,558 | 2,586 |
Shares Change | 1.32% | 0.28% | -3.20% | 0.55% | -1.10% | 2.71% |
EPS (Basic) | 0.18 | 0.19 | 0.25 | 0.23 | 0.14 | 0.78 |
EPS (Diluted) | 0.18 | 0.19 | 0.25 | 0.23 | 0.14 | 0.78 |
EPS Growth | -34.48% | -24.00% | 8.70% | 64.29% | -82.05% | 333.33% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 1,007 | 795.35 | 721.9 | 689.5 | 863.73 | 309.8 |
Free Cash Flow Per Share | 0.40 | 0.32 | 0.29 | 0.27 | 0.34 | 0.12 |
Dividend Per Share | 0.150 | 0.150 | 0.150 | 0.200 | 0.150 | 0.160 |
Dividend Growth | 0% | 0% | -25.00% | 33.33% | -6.25% | - |
Gross Margin | 54.78% | 52.87% | 52.41% | 57.88% | 58.84% | 60.02% |
Operating Margin | 11.05% | 8.18% | 8.91% | 11.95% | 11.51% | 10.26% |
Profit Margin | 6.69% | 7.33% | 9.55% | 8.79% | 5.97% | 30.72% |
Free Cash Flow Margin | 14.75% | 12.29% | 11.08% | 10.24% | 14.39% | 4.72% |
EBITDA | 1,080 | 861.21 | 921.47 | 1,129 | 963.34 | 956.65 |
EBITDA Margin | 15.82% | 13.30% | 14.14% | 16.76% | 16.05% | 14.56% |
D&A For EBITDA | 325.25 | 331.98 | 340.96 | 324.35 | 272.93 | 282.47 |
EBIT | 754.62 | 529.22 | 580.51 | 804.32 | 690.41 | 674.18 |
EBIT Margin | 11.05% | 8.18% | 8.91% | 11.95% | 11.51% | 10.26% |
Effective Tax Rate | 26.28% | 23.81% | 15.59% | 12.11% | 22.02% | 15.48% |
Revenue as Reported | 1,498 | 6,473 | 6,515 | 6,733 | 6,000 | 6,568 |